Arrivo BioVentures

Executive Summary

Arrivo BioVentures is a private biopharmaceutical holding company based in Raleigh, NC, that focuses on developing first-in-class therapeutics for hard-to-treat diseases through its subsidiaries Sirtsei Pharmaceuticals and Panafina Inc. Founded in 2018, the company operates at the Phase 1 stage, with a mission to address root causes of disease and improve patient outcomes. While specific pipeline details are not publicly available, Arrivo's model of providing management oversight and funding to late-stage clinical programs suggests a strategic approach to advancing novel biologics and small molecules. The company's private status and limited public disclosures make it a higher-risk opportunity, but its focus on unmet medical needs and a lean holding structure could enable efficient capital deployment if clinical milestones are achieved.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 2 trial for lead asset50% success
• 2026Strategic partnership or licensing deal40% success